A study of VRDN-003 in participants with active thyroid eye disease (TED) (H-56150)

A phase 3, randomized, double-masked, placebo-controlled, efficacy, safety, and tolerability study of VRDN-003 in participants with active thyroid eye disease (TED)

To determine the efficacy, safety, and tolerability of subcutaneously administered VRDN-003 (VRDN-003 SC) using Q4W or Q8W regimen compared to placebo in participants with active TED.

Approximately 284 participants with active TED will be randomized worldwide.  

To learn more about the REVEAL 1 study, visit clinicaltrials.gov/study/NCT06812325 and contact the study team below.